منابع مشابه
Adjuvant rituximab to prevent TTP relapse.
Acquired TTP is a thrombotic microangiopathy attributable to autoantibody-mediated deficiency of the von Willebrand factor–cleaving protease, a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13). Standard therapy with plasma exchange (PEX), supplemented with corticosteroids, is lifesaving. PEX works by removing anti-ADAMTS13 autoantibody and ultralarge vo...
متن کاملTtp Sim : a Versatile Simulation Environment for Ttp/c
Future electronic systems for the implementation of safety-critical applications on-board automotive vehicles will be based on distributed embedded systems. The most critical component in such systems is the communication network that connects the individual electronic modules. For reasons of costs, composability, ease of validation, and certiication the use of time-triggered communication prot...
متن کاملMitomycin-C-Induced TTP/HUS Treated Successfully with Rituximab: Case Report and Review of the Literature
Microangiopathic hemolytic anemia (MAHA), thrombocytopenia, fever, renal failure, and neurologic symptoms comprise the cardinal features of thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Etiologies can include medications, infections, cancers, or transplantation. We present a patient with a history of rectal cancer treated with mitomycin-C who developed MAHA, acute kidney in...
متن کاملTTP: Tool for Tumor Progression
In this work we present a flexible tool for tumor progression, which simulates the evolutionary dynamics of cancer. Tumor progression implements a multi-type branching process where the key parameters are the fitness landscape, the mutation rate, and the average time of cell division. The fitness of a cancer cell depends on the mutations it has accumulated. The input to our tool could be any fi...
متن کاملRituximab for Treatment of Hemophilia A with High-Responder Inhibitors
Background: The development of inhibitors is a complication factor replacement therapy in hereditary factor VIII deficiency. Several management options are available for the treatment of inhibitor. Rituximab, a monoclonal antibody against CD20, reduces inhibitor level in rare bleeding disorders. The aim of this study was to evaluate the effectiveness of rituximab in lowering or eliminating the ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: American Journal of Hematology
سال: 2005
ISSN: 0361-8609,1096-8652
DOI: 10.1002/ajh.20364